US20040142879A1 - Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus - Google Patents
Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus Download PDFInfo
- Publication number
- US20040142879A1 US20040142879A1 US10/478,372 US47837203A US2004142879A1 US 20040142879 A1 US20040142879 A1 US 20040142879A1 US 47837203 A US47837203 A US 47837203A US 2004142879 A1 US2004142879 A1 US 2004142879A1
- Authority
- US
- United States
- Prior art keywords
- carnitine
- acid
- acetyl
- biotin
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract description 40
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title claims abstract description 21
- 229960002685 biotin Drugs 0.000 title claims abstract description 20
- 235000020958 biotin Nutrition 0.000 title claims abstract description 20
- 239000011616 biotin Substances 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 206010022491 Insulin resistant diabetes Diseases 0.000 title claims abstract description 8
- 239000002253 acid Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- -1 mucate Substances 0.000 claims description 6
- 229940095064 tartrate Drugs 0.000 claims description 6
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- MUZDLCBWNVUYIR-UHFFFAOYSA-L magnesium;2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)C(O)C(O)C([O-])=O MUZDLCBWNVUYIR-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000001227 hypertriglyceridemic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- the present invention relates to the use of acetyl L-carnitine in association with biotin for the treatment of patients suffering from Type 2 insulin-resistant diabetes mellitus
- the diabetes is divided into two main categories:
- Type 1 diabetes Insulin-dependent diabetes mellitus (also known as Type 1 diabetes) which concerns patients suffering from this type of diabetes who literally depend on exogenous insulin to prevent ketoacidosis and death. As far as the endogenous insulin secretion is concerned, patients suffering from Type 1 diabetes mellitus exhibit insulinopenia.
- Noninsulin-dependent diabetes mellitus also known as Type 2 diabetes
- patients with this type of diabetes do not need insulin to live: they can decide whether to use it or not to control the symptoms of the diabetes.
- patients with Type 2 diabetes can be further classified into two groups. In the first group, insulin levels are either normal or lower than normal; in the second group, insulin values are higher than normal and patients exhibit insulin resistance.
- WO 98/01128 discloses the use of the acetyl L-carnitine, isovaleryl L-carnitine, propionil L-carnitine to increase the levels of IGF-1.
- the diabetes is also included in the long list of curable pathologies stated in WO 98/01128.
- WO 98/41113 describes a therapeutic nutritive composition for patients with diabetes mellitus consisting of gamma-linolenic acid, acetyl L-carnitine, mineral salts and vitamins.
- U.S. Pat. No. 4,362,719 describes the use of the L-carnitine and the acyl L-carnitine in treating the juvenile onset diabetes mellitus.
- acetyl L-carnitine a product available on the market, can be prepared by following the method described by R. Krinmberg, and W. Wittandt, in Biochem., Z. 251, 229 (1932).
- an object of the invention is the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, in association with the biotin for the preparation of a medicament for the treatment of Type 2 insulin-resistant diabetes.
- salt of the acetyl L-carnitine is meant any salt of this with an acid that does not give rise to undesirable toxic or side effects. These acids are will known to pharmacologists and to experts in pharmacy.
- Non-limiting examples of these salts are the following: chloride, bromide, orotate, acid aspartate, acid citrate, citrate magnesium, acid phosphate, fumarate and acid fumarate, fumarate magnesium, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, phosphate glucose, tartrate, acid tartrate, tartrate magnesium, 2-amine ethanesulphonate, magnesium 2-amine ethanesulphonate, tartrate coline and trichloroacetate.
- this association shows an unexpected synergic effect, unpredictable on the basis of the knowledge of the use of both compounds, either alone or in association, and can be used as a suitable medicament for the treatment of the Type 2 insulin-resistant diabetes.
- the daily dose to be administered whether one single or multiple, is left to the doctor's judgment according to the weight, age and general condition of the patient, it has been found that the quantity of acetyl L-carnitine to be administered is 0,1 to 2 g/day, while the dose of biotin is 1 to 8 mg/day.
- a preferred amount of the acetyl L-carnitine is 0,2 to 1 g/day, while of the biotin is 3 to 5 mg/day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/216,279 US8053472B2 (en) | 2001-05-29 | 2008-07-02 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000294A ITRM20010294A1 (it) | 2001-05-29 | 2001-05-29 | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
| ITRM2001A000294 | 2001-05-29 | ||
| PCT/IT2002/000338 WO2002096410A1 (en) | 2001-05-29 | 2002-05-24 | Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/216,279 Continuation US8053472B2 (en) | 2001-05-29 | 2008-07-02 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040142879A1 true US20040142879A1 (en) | 2004-07-22 |
Family
ID=11455558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/478,372 Abandoned US20040142879A1 (en) | 2001-05-29 | 2002-05-24 | Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
| US12/216,279 Expired - Fee Related US8053472B2 (en) | 2001-05-29 | 2008-07-02 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/216,279 Expired - Fee Related US8053472B2 (en) | 2001-05-29 | 2008-07-02 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20040142879A1 (enExample) |
| EP (1) | EP1399142B1 (enExample) |
| JP (1) | JP4381685B2 (enExample) |
| KR (1) | KR20040010666A (enExample) |
| AT (1) | ATE333274T1 (enExample) |
| CA (1) | CA2448244C (enExample) |
| CY (1) | CY1105403T1 (enExample) |
| CZ (1) | CZ297743B6 (enExample) |
| DE (1) | DE60213237T2 (enExample) |
| DK (1) | DK1399142T3 (enExample) |
| ES (1) | ES2268053T3 (enExample) |
| HU (1) | HUP0400060A2 (enExample) |
| IT (1) | ITRM20010294A1 (enExample) |
| MX (1) | MXPA03010921A (enExample) |
| PL (1) | PL207522B1 (enExample) |
| PT (1) | PT1399142E (enExample) |
| SK (1) | SK287832B6 (enExample) |
| WO (1) | WO2002096410A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120967A1 (en) * | 2000-12-15 | 2004-06-24 | Menotti Calvani | Use of l-carnitine as stabilizing agent of proteins |
| US20060004095A1 (en) * | 2004-07-01 | 2006-01-05 | Menotti Calvani | Use of acetyl L-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients |
| US20060241058A1 (en) * | 2005-04-26 | 2006-10-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| US20090286726A1 (en) * | 2006-03-10 | 2009-11-19 | Tecnogen S.P.A. | Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546619T3 (es) * | 2007-03-21 | 2015-09-25 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina |
| GB201304112D0 (en) * | 2013-03-07 | 2013-04-24 | Univ Nottingham | Modulation of energy expenditure |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751242A (en) * | 1986-08-04 | 1988-06-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of acetyl L-carnitine in the therapeutical treatment of peripheral neuropathies |
| US5929066A (en) * | 1997-08-08 | 1999-07-27 | Nutrition 21 | Chromium/biotin treatment of Type II diabetes |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
-
2001
- 2001-05-29 IT IT2001RM000294A patent/ITRM20010294A1/it unknown
-
2002
- 2002-05-24 PL PL367630A patent/PL207522B1/pl not_active IP Right Cessation
- 2002-05-24 HU HU0400060A patent/HUP0400060A2/hu unknown
- 2002-05-24 WO PCT/IT2002/000338 patent/WO2002096410A1/en not_active Ceased
- 2002-05-24 ES ES02741155T patent/ES2268053T3/es not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010921A patent/MXPA03010921A/es active IP Right Grant
- 2002-05-24 CA CA2448244A patent/CA2448244C/en not_active Expired - Fee Related
- 2002-05-24 CZ CZ20033221A patent/CZ297743B6/cs not_active IP Right Cessation
- 2002-05-24 US US10/478,372 patent/US20040142879A1/en not_active Abandoned
- 2002-05-24 SK SK1585-2003A patent/SK287832B6/sk not_active IP Right Cessation
- 2002-05-24 EP EP02741155A patent/EP1399142B1/en not_active Expired - Lifetime
- 2002-05-24 JP JP2002592920A patent/JP4381685B2/ja not_active Expired - Fee Related
- 2002-05-24 PT PT02741155T patent/PT1399142E/pt unknown
- 2002-05-24 DK DK02741155T patent/DK1399142T3/da active
- 2002-05-24 KR KR10-2003-7015575A patent/KR20040010666A/ko not_active Ceased
- 2002-05-24 AT AT02741155T patent/ATE333274T1/de active
- 2002-05-24 DE DE60213237T patent/DE60213237T2/de not_active Expired - Lifetime
-
2006
- 2006-09-25 CY CY20061101375T patent/CY1105403T1/el unknown
-
2008
- 2008-07-02 US US12/216,279 patent/US8053472B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751242A (en) * | 1986-08-04 | 1988-06-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of acetyl L-carnitine in the therapeutical treatment of peripheral neuropathies |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| US5929066A (en) * | 1997-08-08 | 1999-07-27 | Nutrition 21 | Chromium/biotin treatment of Type II diabetes |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120967A1 (en) * | 2000-12-15 | 2004-06-24 | Menotti Calvani | Use of l-carnitine as stabilizing agent of proteins |
| US7833977B2 (en) | 2000-12-15 | 2010-11-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of L-Carnitine as stabilizing agent of proteins |
| US20060004095A1 (en) * | 2004-07-01 | 2006-01-05 | Menotti Calvani | Use of acetyl L-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients |
| US20060241058A1 (en) * | 2005-04-26 | 2006-10-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| US8569366B2 (en) * | 2005-04-26 | 2013-10-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| US8952059B2 (en) | 2005-04-26 | 2015-02-10 | Sigma-Tau Industrie Faramceutiche Riunite S.p.A. | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| US20090286726A1 (en) * | 2006-03-10 | 2009-11-19 | Tecnogen S.P.A. | Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases |
| US7910092B2 (en) | 2006-03-10 | 2011-03-22 | Tecnogen S.P.A. | Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases |
| US20110224132A1 (en) * | 2006-03-10 | 2011-09-15 | Tecnogen S.P.A | Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases |
| US8268304B2 (en) | 2006-03-10 | 2012-09-18 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1399142T3 (da) | 2006-10-30 |
| WO2002096410A1 (en) | 2002-12-05 |
| CZ20033221A3 (cs) | 2004-06-16 |
| KR20040010666A (ko) | 2004-01-31 |
| US20080269307A1 (en) | 2008-10-30 |
| ITRM20010294A0 (it) | 2001-05-29 |
| ITRM20010294A1 (it) | 2002-11-29 |
| MXPA03010921A (es) | 2004-02-27 |
| SK15852003A3 (sk) | 2004-04-06 |
| ES2268053T3 (es) | 2007-03-16 |
| CA2448244A1 (en) | 2002-12-05 |
| PT1399142E (pt) | 2006-10-31 |
| EP1399142B1 (en) | 2006-07-19 |
| CY1105403T1 (el) | 2010-04-28 |
| PL207522B1 (pl) | 2010-12-31 |
| HUP0400060A2 (hu) | 2004-04-28 |
| JP4381685B2 (ja) | 2009-12-09 |
| EP1399142A1 (en) | 2004-03-24 |
| CZ297743B6 (cs) | 2007-03-21 |
| JP2004532866A (ja) | 2004-10-28 |
| DE60213237T2 (de) | 2007-08-02 |
| DE60213237D1 (de) | 2006-08-31 |
| CA2448244C (en) | 2010-11-02 |
| ATE333274T1 (de) | 2006-08-15 |
| SK287832B6 (sk) | 2011-11-04 |
| US8053472B2 (en) | 2011-11-08 |
| PL367630A1 (en) | 2005-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK283853B6 (sk) | Terapeutická/výživová kompozícia pre diabetikov | |
| US8053472B2 (en) | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
| EP4331583A1 (en) | Blood carnitine-increasing agent | |
| US20080161604A1 (en) | Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| EP2124925B1 (en) | Composition useful for the treatment of type 2 diabetes | |
| JP7344422B2 (ja) | 糖尿病予防・治療用の医薬品組成物及びその用途 | |
| EP1874288B1 (en) | Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy | |
| US20080287539A1 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
| JPH05194207A (ja) | 特発性精子過少症の処置のためのｌ−カルニチンおよびアシル−ｌ−カルニチンの使用 | |
| CN118871096A (zh) | 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 | |
| JP5685362B2 (ja) | 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン | |
| HK1135030B (en) | Composition useful for the treatment of type 2 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |